Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624990 | 0.85 | — | — | |
| SCHEMBL14004726 | 0.85 | — | — | |
| SCHEMBL29321465 | 0.81 | LMNA (0.47) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14668947 | 0.81 | THRB (0.43) | TDP1 | |
| SCHEMBL7184472 | 0.81 | HSD17B10 (0.41) | MAPK1HSD17B10TDP1TSHRALDH1A1 | |
| SCHEMBL1838790 | 0.80 | SMN1; SMN2 (0.47) | NR2E1SMN1; SMN2MAPK1HSD17B10TDP1 | |
| SCHEMBL1263276 | 0.80 | — | — | |
| SCHEMBL28456948 | 0.80 | — | — | |
| SCHEMBL27338396 | 0.78 | — | — | |
| SCHEMBL6437383 | 0.76 | USP2 (0.47) | HSD17B10TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243050-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | Idera Pharamaceuticals, Inc. (US) | 2016-01-26 | — | — | US | claimed |
| EP-2021008-B1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | claimed |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2014-10-16 | — | — | US | claimed |
| US-8853375-B2 | Toll like receptor modulators | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-8759310-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20130202584-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS, INC. | 2013-08-08 | — | — | US | claimed |
| EP-2179061-B1 | TOLL LIKE RECEPTOR MODULATORS | IDERA PHARMACEUTICALS INC (US) | 2012-10-03 | — | — | EP | claimed |
| US-8106173-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | claimed |
| US-20090053148-A1 | TOLL LIKE RECEPTOR MODULATORS | IDERA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | claimed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | claimed |
| EP-2021008-B1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-5459172-A | Reacting polyol, mixture of glycerin derivatives and water with polyisocyanate in presence of catalyst | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | NR2E1 1493/4885SMN1; SMN2 2543/4885MAPK1 2598/4885 |
| US-20130202584-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | NR2E1 981/4885SMN1; SMN2 400/4885MAPK1 3325/4885 |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | NR2E1 981/4885SMN1; SMN2 400/4885MAPK1 3325/4885 |
| US-20090053148-A1 | TOLL LIKE RECEPTOR MODULATORS | TLR9, TLR3, TLR5 | NR2E1 1218/4885SMN1; SMN2 2079/4885MAPK1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.